Global Dialysis - New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris® (eculizumab) in Patients ... (Centre Daily Times)

New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris® (eculizumab) in Patients ... (Centre Daily Times)

Two separate case reports published today in the New England Journal of Medicine ( NEJM ) examine the investigational use of Soliris ® (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), in patients with a rare and severe inflammatory disease called atypical Hemolytic Uremic Syndrome (aHUS). In both cases, physicians observed a ...